In-licensing Drugs for Personalized Medicine: What You Know, When You Know It
Perlegen says it didn't make sense to do a costly genetic analysis on Mitsubishi's netoglitazone prior to getting rights to the drug. The decision highlights a dilemma for personalized medicine companies pursuing in-licensing, especially those attempting to differentiate a drug from others in its class: How do you assess a drug's potential before you actually have a chance to work with it?
You may also be interested in...
Intense interest in new diabetes drugs gives start-ups many choices for technology development or in-licensing, but recent regulatory caution also increases risk.
Sue Nabi’s success at L’Oreal, where she headed the firm’s global L’Oreal Paris and Lancome businesses, her skin-care savvy as founder of the luxury, “clean, green and vegan” Orveda, and her experience as a career champion of diversity were major draws for Coty, where she begins as CEO on 1 September.